A Multicenter Open-label, Phase I/II Dose Escalation Study of Oral Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 24 Sep 2012
At a glance
- Drugs Docetaxel; Lapatinib
- Indications Advanced breast cancer
- Focus Adverse reactions
- 22 Apr 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 16 Jan 2010 New trial record